Skip to content

Welcome to Discover Pharma! Today is : November 4, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical & Regulatory

  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development

    Rani reports positive Phase 1 data for oral obesity therapy RT-114

    Rani Therapeutics has reported positive initial Phase 1a data for [...]

    July 16, 2026
  • Clinical & Regulatory,Digital & Data,Genomics and sequencing,Research & Development

    Seegene launches global study to evaluate comprehensive PCR testing for respiratory infections

    Seegene has launched the Global Million Clinical Study (GMCS), an [...]

    July 16, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China

    Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

    July 15, 2026
  • Clinical & Regulatory,Research & Development,Therapeutic Areas

    PET imaging reveals widespread synaptic loss in schizophrenia

    Advanced positron emission tomography (PET) imaging has revealed widespread loss [...]

    July 15, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial

    Fractyl Health has reported positive one-year data from the midpoint [...]

    July 16, 2026
  • Clinical & Regulatory,Digital & Data,Research & Development,Therapeutic Areas

    Two-minute digital test matches clinical benchmarks for Alzheimer’s trial screening

    A two-minute digital cognitive assessment developed by Cumulus Neuroscience performed [...]

    July 15, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    EC approves first targeted first-line treatment for BRAF-mutant metastatic colorectal cancer

    The European Commission has approved Erbitux (cetuximab) in combination with [...]

    July 14, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA grants Fast Track status to SOTIO’s colorectal cancer ADC ahead of Phase 1/2 trial

    The US FDA has granted Fast Track Designation to SOTIO [...]

    July 14, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Delivery & Formulation,Research & Development

    EpilepsyGTx partners with ClearPoint Neuro to support Phase 1 gene therapy trial

    EpilepsyGTx has partnered with ClearPoint Neuro to support the targeted [...]

    July 14, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data

    Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]

    July 14, 2026
Previous131415Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SKY-0515 shows 1.59-point cUHDRS difference in Huntington’s disease study
    Categories: Central Nervous System, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • Oncodesign Services and Nexus BioQuest form preclinical research partnership
    Categories: Advanced Therapies, Biotech & Pharma Business, Research & Development
  • Nabsys EGM detects genomic abnormalities in five-sample leukemia study
    Categories: Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top